Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies designed to treat solid tumors by simultaneously targeting multiple pathways within the tumor microenvironment. The company's lead program, ficerafusp alfa, combines EGFR inhibition with a TGF-β ligand trap to block cancer cell proliferation while reducing immunosuppression, allowing immune cells to better infiltrate tumors; the therapy is being evaluated primarily in recurrent and metastatic head and neck squamous cell carcinoma in combination with established checkpoint inhibitors. Bicara generates revenue through regulatory approvals and commercialization of ficerafusp alfa and potential follow-on programs, relying on third-party manufacturers to maintain a capital-efficient operating model and competing against both established oncology therapies and other novel programs in development.